2cureX blog

2cureX Affirms Growth Trajectory with New Partnerships and Direct-to-Patient Model

2cureX AB (Nasdaq First North: 2CUREX), a leader in functional precision oncology, today reaffirmed its strong growth trajectory, driven by the success of its Direct-to-Patient commercial model and the establishment of a strategic stronghold in the field. Management also highlighted that recent industry acquisitions underscore a substantial undervaluation of 2cureX’s unique technology platform in the current market.

Key Highlights

• Direct-to-Patient Model Validated: The company’s pivot to a Direct-to-Patient distribution model in 2024 has accelerated commercial validation. In 2025, the first patient enrolled and received an IndiTreat® test result directly under this new model. Management notes that while initial revenue is modest, it demonstrates clear market demand for 2cureX’s precision oncology solution and lays the foundation for scaling across larger healthcare systems.
• Strategic Partnerships in Functional Precision Oncology: 2cureX AB has established a strategic partnership with 2cureX A/S to offer the IndiTreat® test through the Direct-to-Patient model. This innovative approach is now proven and expanding.

In July 2025, the company also signed a Letter of Intent (LOI) with PreComb Therapeutics AG, a Swiss pioneer in organoid-based drug testing.

Together, these alliances connect two of Europe’s most advanced platforms in 3D functional testing (organoids and tumoroids), creating a comprehensive precision oncology solution spanning early-stage drug development through point-of-care therapy selection.

These collaborations are expected to unlock significant synergies on multiple fronts.

PreComb’s strong relationships in the pharma and biotech sector complement 2cureX A/S’s hospital presence, opening the door to pharma-sponsored trials using IndiTreat® across multiple cancer types. By combining these platforms, 2cureX AB aims to become an indispensable partner for both drug developers and clinicians, delivering personalized treatment guidance across the cancer care continuum.

• Industry Acquisitions Highlight Undervaluation: Recent M&A activity in precision oncology demonstrates the rising value of functional testing platforms. For example, in January 2025, GlaxoSmithKline (GSK) acquired German organoid testing firm CELLphenomics for approximately €44 million. Similar acquisitions by companies such as Tempus signal strong investor appetite for functional drug testing platforms. 2cureX management believes that, given its advanced clinical presence, the company remains significantly undervalued relative to peers.

Leadership Commentary

Nathaniel Hutley, Interim CEO of 2cureX, commented:

“2024 was the year 2cureX transformed. The first half of 2025 proved that our new strategy has moved beyond just a vision and is working. We have validated our Direct-to-Patient model, connected to the pharmaceutical industry through our PreComb partnership, and positioned IndiTreat® at the center of a fast-emerging precision oncology market. Patients are engaging. Pharma is preparing trials. Investors are leaning in.”

Ole Thastrup, Chairman of 2cureX AB, added:
“By exploring this alliance with PreComb, we are setting the stage for the next chapter in oncology. Functional precision testing should be the clinical standard — not the exception. This collaboration allows us to deliver on that vision faster, and at scale.”

Clinical Pipeline and Investor Outlook

As further evidence of industry confidence, 2cureX continues to enjoy strong investor support. The Board of Directors is actively evaluating strategic opportunities to maximize shareholder value, including potential partnerships or acquisition offers, given high interest in the sector. At the same time, the company is exploring and is open to bolt-on acquisitions that could enhance its portfolio and expand market reach.

Outlook: Positioned for Growth

Building on fresh revenue streams, transformative partnerships, and expanding clinical programs, 2cureX enters its next phase of growth with confidence. Following the strategic reset in 2024 — which decentralized IndiTreat® testing to local hospitals and strengthened pharma ties — the company is focused on a clear set of priorities:

• Broaden Patient Access: Expand Direct-to-Patient IndiTreat® testing across major European healthcare systems, increasing accessibility for cancer patients and oncologists. This expansion is expected to drive revenue growth as awareness increases, and more hospitals adopt the test.
• Advance Pharma Collaborations: Execute pharma-driven clinical trials with PreComb Therapeutics in multiple cancer indications, reinforcing IndiTreat®’s role in drug development and potentially yielding collaborative revenue streams.
• Regulatory Milestones: Support 2cureX A/S in achieving CE-IVDR regulatory approvals under EU diagnostic regulations, enabling broader adoption and reimbursement.
• Operational Innovation: Integrate AI and automation to improve efficiency, reduce costs, and shorten turnaround times, enhancing the company’s competitive edge.
• Strengthen Leadership: Attract additional tier-1 talent to support international growth and solidify global leadership. Building a world-class team will support the company’s ambitions to become a global precision oncology leader.
• Strategic Expansion: Pursue acquisitions and partnerships that complement IndiTreat®, such as novel biomarkers, AI analytics, and distribution channels, to accelerate growth and broaden the company’s market presence.

With these initiatives underway, 2cureX is well-positioned to drive the adoption of functional precision oncology as a global standard of care in cancer treatment worldwide, and to ensure that every cancer patient gets the right therapy at the right time.

By delivering measurable progress — from first revenues to high-value alliances — the company continues to build confidence among patients, physicians, and investors alike.